Cargando…

A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain

Interactions between SH2 domains and phosphotyrosine sites regulate tyrosine kinase signaling networks. Selective perturbation of these interactions is challenging due to the high homology among the 120 human SH2 domains. Using an improved phage-display selection system, we generated a small antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojcik, John, Hantschel, Oliver, Grebien, Florian, Kaupe, Ines, Bennett, Keiryn L., Barkinge, John, Jones, Richard B., Koide, Akiko, Superti-Furga, Giulio, Koide, Shohei
Formato: Texto
Lenguaje:English
Publicado: 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926940/
https://www.ncbi.nlm.nih.gov/pubmed/20357770
http://dx.doi.org/10.1038/nsmb.1793
_version_ 1782185738813571072
author Wojcik, John
Hantschel, Oliver
Grebien, Florian
Kaupe, Ines
Bennett, Keiryn L.
Barkinge, John
Jones, Richard B.
Koide, Akiko
Superti-Furga, Giulio
Koide, Shohei
author_facet Wojcik, John
Hantschel, Oliver
Grebien, Florian
Kaupe, Ines
Bennett, Keiryn L.
Barkinge, John
Jones, Richard B.
Koide, Akiko
Superti-Furga, Giulio
Koide, Shohei
author_sort Wojcik, John
collection PubMed
description Interactions between SH2 domains and phosphotyrosine sites regulate tyrosine kinase signaling networks. Selective perturbation of these interactions is challenging due to the high homology among the 120 human SH2 domains. Using an improved phage-display selection system, we generated a small antibody-mimic or ‘monobody’, termed HA4, that bound to the Abl kinase SH2 domain with low nanomolar affinity. SH2 protein microarray analysis and mass spectrometry of intracellular HA4 interactors demonstrated HA4's exquisite specificity, and a crystal structure revealed how this specificity is achieved. HA4 disrupted intramolecular interactions of Abl involving the SH2 domain and potently activated the kinase in vitro. Within cells, HA4 inhibited processive phosphorylation activity of Abl and also STAT5 activation. This work provides a design guideline for highly specific and potent inhibitors of a protein interaction domain and demonstrates their utility in mechanistic and cellular investigations.
format Text
id pubmed-2926940
institution National Center for Biotechnology Information
language English
publishDate 2010
record_format MEDLINE/PubMed
spelling pubmed-29269402010-10-01 A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain Wojcik, John Hantschel, Oliver Grebien, Florian Kaupe, Ines Bennett, Keiryn L. Barkinge, John Jones, Richard B. Koide, Akiko Superti-Furga, Giulio Koide, Shohei Nat Struct Mol Biol Article Interactions between SH2 domains and phosphotyrosine sites regulate tyrosine kinase signaling networks. Selective perturbation of these interactions is challenging due to the high homology among the 120 human SH2 domains. Using an improved phage-display selection system, we generated a small antibody-mimic or ‘monobody’, termed HA4, that bound to the Abl kinase SH2 domain with low nanomolar affinity. SH2 protein microarray analysis and mass spectrometry of intracellular HA4 interactors demonstrated HA4's exquisite specificity, and a crystal structure revealed how this specificity is achieved. HA4 disrupted intramolecular interactions of Abl involving the SH2 domain and potently activated the kinase in vitro. Within cells, HA4 inhibited processive phosphorylation activity of Abl and also STAT5 activation. This work provides a design guideline for highly specific and potent inhibitors of a protein interaction domain and demonstrates their utility in mechanistic and cellular investigations. 2010-03-28 2010-04 /pmc/articles/PMC2926940/ /pubmed/20357770 http://dx.doi.org/10.1038/nsmb.1793 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Wojcik, John
Hantschel, Oliver
Grebien, Florian
Kaupe, Ines
Bennett, Keiryn L.
Barkinge, John
Jones, Richard B.
Koide, Akiko
Superti-Furga, Giulio
Koide, Shohei
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
title A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
title_full A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
title_fullStr A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
title_full_unstemmed A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
title_short A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
title_sort potent and highly specific fn3 monobody inhibitor of the abl sh2 domain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926940/
https://www.ncbi.nlm.nih.gov/pubmed/20357770
http://dx.doi.org/10.1038/nsmb.1793
work_keys_str_mv AT wojcikjohn apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT hantscheloliver apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT grebienflorian apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT kaupeines apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT bennettkeirynl apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT barkingejohn apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT jonesrichardb apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT koideakiko apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT supertifurgagiulio apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT koideshohei apotentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT wojcikjohn potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT hantscheloliver potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT grebienflorian potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT kaupeines potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT bennettkeirynl potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT barkingejohn potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT jonesrichardb potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT koideakiko potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT supertifurgagiulio potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain
AT koideshohei potentandhighlyspecificfn3monobodyinhibitoroftheablsh2domain